Senator Warren Urges FTC Review of Novo's $16.5B Catalent Merger Amid Antitrust Concerns

Senator Elizabeth Warren has expressed significant concerns over Novo Holdings' proposed $16.5 billion acquisition of Catalent, urging the Federal Trade Commission (FTC) to closely scrutinize the merger[1][2]. She fears that the acquisition could bolster Novo Nordisk's control over the GLP-1 market, potentially reducing competition and raising prices for critical medications like Ozempic and Wegovy[1]. Warren is particularly concerned that the deal might impact Eli Lilly's supply chain, as they currently rely on Catalent for some GLP-1 products[1]. The acquisition aims to increase production capacity, which Warren believes could lead to diminished competition and an affordability crisis[2].